Presentations highlight the pathogenic role of the CD6-ALCAM pathway, the immunologic impact of modulating this pathway with itolizumab, and pharmacodynamic assays to monitor this in patients
top of page
Search
Recent Posts
See AllInterim results of a Phase 1b trial of cirmtuz umab and paclitaxel in locally advanced/unresectable or metastatic HER2-negative breast...
- First quarter of full complement of 60 sales representatives further expanding the reach of XENLETA® (lefamulin) and SIVEXTRO®...
MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced the hiring of Joyce...
bottom of page
Commentaires